Vyvgart Hytrulo is FDA-approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). It is given once a week as a shot under the skin. Vyvgart Hytrulo may also be ...

Argenx is urging patients to “Live Vyvidly.” The biotech put the message out in a direct-to-consumer TV ad that paints ...

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Albert Fiori was diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy or CIDP, a rare autoimmune disease that affects his eye, one arm and one leg. But he is not letting that stop him from ...

Polar Capital Global Healthcare, which is co-managed by James Douglas, currently trades at a 3pc discount to its assets.

Valeo Financial Advisors LLC bought a new stake in argenx SE (NASDAQ:ARGX – Free Report) during the 4th quarter, according to ...

Gibraltarian John Navarro, 38, is the only person on the Rock with multi-focal motor neuropathy (MMN) and, one year post ...

Halozyme Therapeutics' record-breaking 2024 revenue exceeded $1B, with strong 2025 growth projections led by DARZALEX & VYVGART.

"The suicides are a result of not knowing there is support, not being able to reach out for help to access the support that ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.